Skip to main content
. 2015 Feb 12;3(1):10–15. doi: 10.1016/j.prnil.2015.02.006

Fig. 2.

Fig. 2

Comparative survival curves of patients with bone metastatic prostate cancer for cancer-specific survival. (A) Survival curve stratified according to serum prostate-specific antigen (PSA) levels. (B) Survival curve stratified according to. serum alkaline phosphatase (ALP) levels dichotomized at 200 IU/L. (C) Survival curve stratified according to. PSA nadir levels dichotomized at 0.2 ng/mL. (D) Survival curve stratified according to time to PSA nadir (TTN) dichotomized at 9 months.